Shionogi & Co (4507.T) Stock Price

Shionogi & Co Price

JPX·CLOSED
2,859.00JPY+28.00 (+0.98 %)
Market closed

Over the last 19 years Shionogi & Co grew revenue by 4.3% annually, reaching 438.27 B JPY. Earnings per share have grown at 6.0% per year over the last 19 years. For Shionogi & Co, the net margin of 38.9% is up versus 37.6% a few years ago. At today's price the dividend yield works out to roughly 2.31%. The payout ratio is around 33% of earnings. The dividend has grown at 7.1% per year over the past 19 years. The consensus 12-month price target for Shionogi & Co is 3,162.00 JPY, about 10.6% above where the stock trades today. Of 17 analysts, 7 rate the stock a buy — an overall Hold consensus. The stock trades about 19% above its 52-week low.

Shionogi & Co stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Shionogi & Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Shionogi & Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Shionogi & Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Shionogi & Co Stock Price History
DateShionogi & Co Price
8/19/20262,859.00 JPY
8/18/20262,831.00 JPY
8/17/20262,803.50 JPY
8/14/20262,831.50 JPY
8/13/20262,819.00 JPY
8/12/20262,802.50 JPY
8/10/20262,851.00 JPY
8/7/20262,810.00 JPY
8/6/20262,772.00 JPY
8/5/20262,759.00 JPY
8/4/20262,775.00 JPY
8/3/20262,870.50 JPY
7/31/20262,908.50 JPY
7/30/20263,005.00 JPY
7/29/20263,070.00 JPY
7/28/20262,902.50 JPY
7/27/20262,892.50 JPY
7/24/20262,855.50 JPY
7/23/20262,848.00 JPY
7/22/20262,876.00 JPY
7/21/20262,906.50 JPY
7/17/20262,876.00 JPY
7/16/20262,842.50 JPY
7/15/20262,840.50 JPY
7/14/20262,864.00 JPY
7/13/20262,821.00 JPY
7/10/20262,821.50 JPY
7/9/20262,816.00 JPY
7/8/20262,887.00 JPY
7/7/20262,909.00 JPY
7/6/20262,923.00 JPY
7/3/20262,886.00 JPY
7/2/20262,792.00 JPY
7/1/20262,729.00 JPY
6/30/20262,769.50 JPY
6/29/20262,810.50 JPY
6/26/20262,739.50 JPY
6/25/20262,746.00 JPY
6/24/20262,818.00 JPY
6/23/20262,819.50 JPY
6/22/20262,812.00 JPY
6/19/20262,791.50 JPY
6/18/20262,838.50 JPY
6/17/20262,828.50 JPY
6/16/20262,811.50 JPY
6/15/20262,795.50 JPY
6/12/20262,773.00 JPY
6/11/20262,768.50 JPY
6/10/20262,789.00 JPY
6/9/20262,768.00 JPY
6/8/20262,858.00 JPY
6/5/20262,857.50 JPY
6/4/20262,843.50 JPY
6/3/20262,812.00 JPY
6/2/20262,828.00 JPY
6/1/20262,849.00 JPY
5/29/20263,024.00 JPY
5/28/20263,017.00 JPY
5/27/20263,035.00 JPY
5/26/20263,012.00 JPY
5/25/20263,002.00 JPY
5/22/20262,960.50 JPY
5/21/20263,009.00 JPY
5/20/20263,066.00 JPY
5/19/20263,028.00 JPY
5/18/20263,049.00 JPY
5/15/20263,070.00 JPY
5/14/20263,055.00 JPY
5/13/20262,978.00 JPY
5/12/20263,171.00 JPY
5/11/20263,207.00 JPY
5/8/20263,177.00 JPY
5/7/20263,151.00 JPY
5/1/20263,128.00 JPY
4/30/20263,170.00 JPY
4/28/20263,180.00 JPY
4/27/20263,075.00 JPY
4/24/20263,110.00 JPY
4/23/20263,094.00 JPY
4/22/20263,086.00 JPY
4/21/20263,128.00 JPY
4/20/20263,213.00 JPY
4/17/20263,220.00 JPY
4/16/20263,276.00 JPY
4/15/20263,299.00 JPY
4/14/20263,327.00 JPY
4/13/20263,375.00 JPY
4/10/20263,371.00 JPY
4/9/20263,478.00 JPY
4/8/20263,606.00 JPY
4/7/20263,618.00 JPY
4/6/20263,580.00 JPY
4/3/20263,562.00 JPY
3/27/20263,515.00 JPY
3/26/20263,457.00 JPY
3/25/20263,441.00 JPY
3/24/20263,319.00 JPY
3/23/20263,256.00 JPY
3/19/20263,367.00 JPY
3/18/20263,509.00 JPY
3/17/20263,474.00 JPY
3/16/20263,410.00 JPY
3/13/20263,409.00 JPY
3/12/20263,404.00 JPY
3/11/20263,459.00 JPY
3/9/20263,389.00 JPY
3/6/20263,451.00 JPY
3/5/20263,440.00 JPY
2/27/20263,664.00 JPY
2/26/20263,648.00 JPY
2/25/20263,664.00 JPY
2/24/20263,630.00 JPY
2/20/20263,645.00 JPY
2/19/20263,642.00 JPY
2/18/20263,575.00 JPY
2/17/20263,477.00 JPY
2/16/20263,450.00 JPY
2/13/20263,536.00 JPY
2/12/20263,535.00 JPY
2/10/20263,494.00 JPY
2/9/20263,521.00 JPY
2/6/20263,393.00 JPY
2/5/20263,428.00 JPY
2/4/20263,373.00 JPY
2/3/20263,346.00 JPY
2/2/20263,217.00 JPY
1/30/20263,174.00 JPY
1/29/20263,116.00 JPY
1/28/20263,078.00 JPY
1/27/20263,150.00 JPY
1/26/20263,112.00 JPY
1/23/20263,150.00 JPY
1/22/20263,025.00 JPY
1/21/20262,901.50 JPY
1/20/20262,920.50 JPY
1/19/20262,840.50 JPY
1/16/20262,862.50 JPY
1/15/20262,938.00 JPY
1/14/20262,942.00 JPY
1/13/20262,895.50 JPY
1/9/20262,907.00 JPY
1/8/20262,924.50 JPY
1/7/20262,842.50 JPY
1/6/20262,846.50 JPY
1/5/20262,865.00 JPY
12/30/20252,841.00 JPY
12/29/20252,832.50 JPY
12/26/20252,849.00 JPY
12/25/20252,859.00 JPY
12/24/20252,776.00 JPY
12/23/20252,788.50 JPY
12/22/20252,705.00 JPY
12/19/20252,716.00 JPY
12/18/20252,739.00 JPY
12/17/20252,719.00 JPY
12/16/20252,764.00 JPY
12/15/20252,742.00 JPY
12/12/20252,676.50 JPY
12/11/20252,661.00 JPY
12/10/20252,678.00 JPY
12/9/20252,808.50 JPY
12/8/20252,685.00 JPY
12/5/20252,651.50 JPY
12/4/20252,694.50 JPY
12/3/20252,630.00 JPY
12/2/20252,640.00 JPY
12/1/20252,621.50 JPY
11/28/20252,680.50 JPY
11/27/20252,690.50 JPY
11/26/20252,760.00 JPY
11/25/20252,733.00 JPY
11/21/20252,697.00 JPY
11/20/20252,718.50 JPY
11/19/20252,688.50 JPY
11/18/20252,706.00 JPY
11/17/20252,685.00 JPY
11/14/20252,733.00 JPY
11/13/20252,732.00 JPY
11/12/20252,689.00 JPY
11/11/20252,648.00 JPY
11/10/20252,647.00 JPY
11/7/20252,607.00 JPY
11/6/20252,624.00 JPY
11/5/20252,594.50 JPY
11/4/20252,581.00 JPY
10/31/20252,580.00 JPY
10/30/20252,483.50 JPY
10/29/20252,487.00 JPY
10/28/20252,494.00 JPY
10/27/20252,483.00 JPY
10/24/20252,443.00 JPY
10/23/20252,451.00 JPY
10/22/20252,450.00 JPY
10/21/20252,454.50 JPY
10/20/20252,445.50 JPY
10/17/20252,399.00 JPY
10/16/20252,416.00 JPY
10/15/20252,418.00 JPY
10/14/20252,420.00 JPY
10/10/20252,484.00 JPY
10/9/20252,541.00 JPY
10/8/20252,545.00 JPY
10/7/20252,596.00 JPY
10/6/20252,598.50 JPY
10/3/20252,507.50 JPY
10/2/20252,490.00 JPY
10/1/20252,555.00 JPY
9/30/20252,591.50 JPY
9/29/20252,585.50 JPY
9/26/20252,639.50 JPY
9/25/20252,612.50 JPY
9/24/20252,666.50 JPY
9/22/20252,640.50 JPY
9/19/20252,702.00 JPY
9/18/20252,649.50 JPY
9/17/20252,613.50 JPY
9/16/20252,616.50 JPY
9/12/20252,658.50 JPY
9/11/20252,663.00 JPY
9/10/20252,658.00 JPY
9/9/20252,680.50 JPY
9/8/20252,693.50 JPY
9/5/20252,665.00 JPY
9/4/20252,598.50 JPY
9/3/20252,592.50 JPY
9/2/20252,559.00 JPY
9/1/20252,559.00 JPY
8/29/20252,550.00 JPY
8/28/20252,560.50 JPY
8/27/20252,553.50 JPY
8/26/20252,540.00 JPY
8/25/20252,571.00 JPY
8/22/20252,580.50 JPY
Access this data via the Eulerpool API
Get Free API Key

Shionogi & Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
426.68 B JPY
159.25 B JPY
184.97 B JPY
Jan 1, 2024
435.08 B JPY
168.38 B JPY
162.03 B JPY
Jan 1, 2025
438.27 B JPY
159.32 B JPY
170.44 B JPY
Jan 1, 2026 (e)
503.14 B JPY
310.37 B JPY
195.92 B JPY
Jan 1, 2027 (e)
699.13 B JPY
431.27 B JPY
213.78 B JPY
Jan 1, 2028 (e)
732.55 B JPY
451.88 B JPY
234.67 B JPY
Jan 1, 2029 (e)
738.76 B JPY
455.71 B JPY
239.54 B JPY
Jan 1, 2030 (e)
739.11 B JPY
455.93 B JPY
235.10 B JPY

Shionogi & Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 21, 2026, 10:50 AM
 
REVENUEB JPY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB JPY
EBITB JPY
EBIT MARGIN%
NET INCOMEB JPY
NET INCOME GROWTH%
DIV.JPY
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
309.97338.89344.67367.96333.37297.18335.14426.68435.08438.27503.14699.13732.55738.76739.11730.81
13.139.331.706.76-9.40-10.8612.7727.321.970.7314.8038.954.780.850.05-1.12
75.8877.0578.5684.8982.9782.3383.4785.4186.7685.4485.4485.4485.4485.4485.4485.44
235.22261.11270.76312.37276.59244.65279.72364.44377.48374.44429.87597.32625.87631.17631.47624.38
91.41108.18115.22163.60128.71118.72110.67159.25168.38159.32310.37431.27451.88455.71455.93450.81
29.4931.9233.4344.4638.6139.9533.0237.3238.7036.3561.6961.6961.6961.6961.6961.69
66.6983.88108.87137.19122.19111.86114.19184.97162.03170.44195.92213.78234.67239.54235.10154.79
51.3525.7829.7926.02-10.93-8.462.0861.99-12.405.1914.959.119.772.07-1.85-34.16
68.0076.0088.00100.00106.00110.00120.00150.00113.3366.00104.00124.80149.76–––
21.4311.7615.7913.646.003.779.0925.00-24.45-41.7657.5820.0020.00–––
330.57327.77322.60315.58309.13306.55904.75893.42870.64850.94850.94850.94850.94850.94850.94850.94
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Shionogi & Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Shionogi & Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Shionogi & Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Shionogi & Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Shionogi & Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Shionogi & Co stock margins

The Shionogi & Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shionogi & Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shionogi & Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
82.33 %
39.95 %
37.64 %
Jan 1, 2022
83.47 %
33.02 %
34.07 %
Jan 1, 2023
85.41 %
37.32 %
43.35 %
Jan 1, 2024
86.76 %
38.70 %
37.24 %
Jan 1, 2025
85.44 %
36.35 %
38.89 %
Jan 1, 2026 (e)
85.44 %
61.69 %
38.94 %
Jan 1, 2027 (e)
85.44 %
61.69 %
30.58 %
Jan 1, 2028 (e)
85.44 %
61.69 %
32.03 %

Shionogi & Co Stock Revenue, EBIT, Earnings per Share

The Shionogi & Co earnings per share therefore indicates how much revenue Shionogi & Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
969.41 JPY
387.29 JPY
364.89 JPY
Jan 1, 2022
370.42 JPY
122.32 JPY
126.21 JPY
Jan 1, 2023
477.58 JPY
178.24 JPY
207.03 JPY
Jan 1, 2024
499.72 JPY
193.39 JPY
186.10 JPY
Jan 1, 2025
515.04 JPY
187.23 JPY
200.29 JPY
Jan 1, 2026 (e)
591.28 JPY
364.74 JPY
230.24 JPY
Jan 1, 2027 (e)
821.60 JPY
506.81 JPY
251.22 JPY
Jan 1, 2028 (e)
860.87 JPY
531.04 JPY
275.77 JPY

Shionogi & Co business model & stock analysis

The company Shionogi & Co Ltd is a Japanese pharmaceutical company based in Osaka. It was founded in 1878 and has since become a significant player in the industry. It currently employs over 6,000 employees worldwide and is listed on the Tokyo Stock Exchange. Shionogi is divided into several business segments that offer different products and services. The largest segment is the pharmaceutical division, which specializes in the development and marketing of drugs. The company has strong expertise in infectious diseases, pain management, and oncology, and operates in many countries worldwide. One flagship product is the antibiotic Cefditoren, used to treat various bacterial infections. In addition to the pharmaceutical division, Shionogi is also active in other areas. For example, the company offers diagnostic and laboratory services, operating multiple labs in Japan and other countries. Another business segment is the production and marketing of nutritional supplements, sold in Japan, China, and the USA. Shionogi's business model is based on extensive research and development, as well as strong brand positioning. The company invests a significant portion of its revenue each year in the research and development of new drugs and better treatment options for existing diseases. Thanks to the high quality of its products and strong brand, the company has a loyal customer base. In recent years, Shionogi has focused on international expansion opportunities and has expanded its activities in various regions. For example, it has partnered with US pharmaceutical company Purdue Pharma to develop and market a novel pain medication. Shionogi's annual revenue is around 1.5 billion euros. The company is particularly strong in Japan and other Asian countries, but is also active in the US and Europe. In the coming years, Shionogi aims to further expand its international business and solidify its position as a significant player in the industry. Key focuses will be on the launch of new products and finding treatments for previously incurable diseases. Overall, Shionogi is an innovative and successful company that utilizes its expertise in the pharmaceutical industry in various ways. With its dedicated employees and strong brand, it will continue to play an important role in the industry.

Shionogi & Co SWOT Analysis

Strengths

[ { "heading": "1.", "text": "Strong" }, { "heading": "2.", "text": "Diverse" }, { "heading": "3.", "text": "Robust" }, { "heading": "4.", "text": "Well-established" }, { "heading": "5.", "text": "Effective" } ]

Weaknesses

[ { "heading": "1.", "text": "Vulnerability" }, { "heading": "2.", "text": "Limited" }, { "heading": "3.", "text": "High" }, { "heading": "4.", "text": "Potential" }, { "heading": "5.", "text": "Lack" } ]

Opportunities

[ { "heading": "1.", "text": "Expansion" }, { "heading": "2.", "text": "Collaboration" }, { "heading": "3.", "text": "Increasing" }, { "heading": "4.", "text": "Mergers" }, { "heading": "5.", "text": "Potential" } ]

Threats

[ { "heading": "1.", "text": "Intense" }, { "heading": "2.", "text": "Regulatory" }, { "heading": "3.", "text": "Economic" }, { "heading": "4.", "text": "Rapid" }, { "heading": "5.", "text": "Increasing" } ]

Shionogi & Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Shionogi & Co historical P/E ratio, EBIT multiple, and P/S ratio

Shionogi & Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Shionogi & Co shares outstanding

The number of shares of Shionogi & Co was 850.94 M in 2025. This indicates how many shares Shionogi & Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
306.55 M Stocks
Jan 1, 2022
904.75 M Stocks
Jan 1, 2023
893.42 M Stocks
Jan 1, 2024
870.64 M Stocks
Jan 1, 2025
850.94 M Stocks
Jan 1, 2026 (e)
850.94 M Stocks
Jan 1, 2027 (e)
850.94 M Stocks
Jan 1, 2028 (e)
850.94 M Stocks

Shionogi & Co stock splits

In Shionogi & Co's history, there have been no stock splits.

Shionogi & Co Dividend History

37 years of dividend payments

YearAnnual DividendYoY ChangePayments
202633.00JPYYTD—1×
Mar 30, 202633.00JPY 0.0%1/1
202566.00JPY↓ 41.8%2×
Mar 28, 202533.00JPY↑ 16.5%1/2
Sep 29, 202533.00JPY 0.0%2/2
2024113.33JPY↓ 24.4%2×
2023150.00JPY↑ 25.0%2×
2022120.00JPY↑ 9.1%2×
2021110.00JPY↑ 3.8%2×
2020106.00JPY↑ 6.0%2×
2019100.00JPY↑ 13.6%2×
201888.00JPY↑ 15.8%2×
201776.00JPY↑ 11.8%2×

Shionogi & Co dividend history and estimates

In 2025, Shionogi & Co paid a dividend amounting to 66.00 JPY. Dividend means that Shionogi & Co distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
110.00 JPY
0.00 JPY
Jan 1, 2022
120.00 JPY
0.00 JPY
Jan 1, 2023
150.00 JPY
0.00 JPY
Jan 1, 2024
113.33 JPY
0.00 JPY
Jan 1, 2025
66.00 JPY
0.00 JPY
Jan 1, 2026
104.00 JPY
0.00 JPY
Jan 1, 2027 (e)
0.00 JPY
124.80 JPY
Jan 1, 2028 (e)
0.00 JPY
149.76 JPY

Shionogi & Co dividend payout ratio

In 2025, Shionogi & Co had a payout ratio of 32.95%. The payout ratio indicates the percentage of the company's profits that Shionogi & Co distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
9.87 %
Jan 1, 2022
31.69 %
Jan 1, 2023
24.15 %
Jan 1, 2024
30.45 %
Jan 1, 2025
32.95 %
Jan 1, 2026 (e)
45.17 %
Jan 1, 2027 (e)
49.68 %
Jan 1, 2028 (e)
54.31 %

Current Shionogi & Co forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
6.90 %
Buy
41.18 % (7)
Hold
58.82 % (10)
Sell
0.00 % (0)
12M Price Target
3,162.00
Last Price
2,926.00
Currency
JPY
12M Return Potential
8.07 %
LTM Return
0 %

Shionogi & Co Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/8/2024153.05JPY-114.87 BJPY-2024 Q4
1/29/2024112.86JPY-83.00 BJPY-2024 Q3
7/31/2023117.87JPY-96.42 BJPY-2024 Q1
5/9/2023140.81JPY-130.14 BJPY-2023 Q4
1/30/2023116.89JPY-96.98 BJPY-2023 Q3
10/31/202269.12JPY-79.03 BJPY-2023 Q2
8/1/202281.37JPY-70.46 BJPY-2023 Q1
5/11/2022126.67JPY-102.42 BJPY-2022 Q4
1/31/202281.17JPY-76.35 BJPY-2022 Q3
11/1/202176.98JPY-73.39 BJPY-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the Shionogi & Co stock

92/100
99
Environment
99
Social
79
Governance
E

Environment

20
Scope 1 - Direct Emissions41,376
Scope 2 - Indirect emissions from purchased energy48,212
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions89,589
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees34.5
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Shionogi & Co shareholder structure

% Name
5.98601%
Nomura Asset Management Co., Ltd.
Nomura Asset Management Co., Ltd.
2.99312%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.81504%
Daiwa Asset Management Co., Ltd.
Daiwa Asset Management Co., Ltd.
1.95389%
Wellington Management Company, LLP
Wellington Management Company, LLP
1.26083%
Mitsubishi UFJ Asset Management Co., Ltd.
Mitsubishi UFJ Asset Management Co., Ltd.
1.10163%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
...

Shionogi & Co Beneficial Ownership Filings (SEC 13D/G)

Free Float
78.5%
Float Shares
-
Shares Outstanding
-

Shionogi & Co Executives and Management Board

23 members · avg. age 66 · 13 % women

IT

Mr. Isao Teshirogi (64)

Chairman of the Board, President, Chief Executive Officer, Representative Director · since 2007

272.00 M JPY

Management

KH

Mr. Koji Hanasaki

Senior Executive Officer

–
KH

Mr. Kazuhiro Hatanaka (59)

Senior Executive Officer, Chief Director of Corporate Strategy

–
YI

Mr. Yasuyoshi Isou

Senior Executive Officer, Chief Director of Drug Discovery Research

–
TI

Mr. Toshinobu Iwasaki

Senior Executive Officer

–
AK

Mr. Akira Kato

Senior Executive Officer, President of Subsidiary

–
JK

Mr. John Keller

Senior Executive Officer

–

Board of Directors

TS

Ms. Takuko Sawada (69)

Vice Chairman of the Board · since 2011

157.00 M JPY
KA

Mr. Keiichi Ando (72)

Independent Director

–
TF

Mr. Takaoki Fujiwara (72)

Independent Director

–
HO

Mr. Hiroshi Ozaki (74)

Independent Director

–
FT

Ms. Fumi Takatsuki (49)

Independent Director

–
MK

Ms. Masako Kudo

Director of Finance and Accounting · since 2023

–

Shionogi & Co Supply Chain

Shionogi & Co Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
30 companies
#Nameβ 1YTrend
1
Accenture A
Supplier·IT Services·IE
-0.21
0.47
0.38
0.44
0.69
0.72
0.86
2
Eli Lilly
Supplier·Customer·Pharmaceuticals·US
0.56
0.70
-0.51
-0.16
0.38
0.67
0.42
3
Nissan Chemical
Supplier·Chemicals·JP
-0.77
-0.47
-0.36
0.13
0.80
0.66
0.98
4
Mitsubishi UFJ Financial Group
Supplier·Customer·Banks·JP
-0.57
-0.27
-0.04
-0.33
0.46
0.64
0.53
5
GlaxoSmithKline
Supplier·Customer·Pharmaceuticals·GB
0.69
-0.01
-0.51
-0.42
0.48
0.61
—
#Nameβ 1YTrend
1
Advanz Pharma Corp. Ltd.
Customer·GB
0.26
-0.42
-0.56
—
—
—
—
2
Certara
Supplier·Health Care Technology·US
-0.41
0.31
0.57
0.24
0.12
—
—
3
FunPep
Supplier·Customer·Biotechnology·JP
-0.54
0.53
0.36
0.33
-0.68
—
—
4
PeptiDream
Supplier·Customer·Biotechnology·JP
0.61
0.49
0.16
0.50
-0.79
-0.83
-1.30
5
Ping An Insurance Group H
Supplier·Customer·CN
-0.06
0.49
0.68
0.09
-0.80
-0.82
—

Frequently asked questions about Shionogi & Co

Shionogi & Co Ltd is a pharmaceutical company that focuses on developing and marketing innovative drugs. Their business model revolves around research and development, manufacturing, and sales of pharmaceutical products. Shionogi aims to provide solutions to unmet medical needs by focusing on therapeutic areas such as infectious diseases, pain, cardiovascular disorders, and oncology. By investing in cutting-edge research, Shionogi strives to create new treatments and improve existing therapies. With a strong commitment to quality and patient-centric approach, Shionogi seeks to contribute to the well-being of society by delivering safe, effective, and high-quality pharmaceutical products.

Shionogi & Co Ltd is primarily active in the pharmaceutical industry.

The main competitors of Shionogi & Co Ltd in the market include Takeda Pharmaceutical Co Ltd, Astellas Pharma Inc., and Daiichi Sankyo Co Ltd.

Shionogi & Co Ltd is a renowned pharmaceutical company based in Japan. With a rich history dating back to 1878, Shionogi has established itself as a leading player in the global healthcare industry. The company is known for its focus on research and development, aiming to discover innovative solutions to various medical challenges. Shionogi's commitment to addressing unmet medical needs has led to the development of groundbreaking drugs and treatments. Over the years, Shionogi has expanded its operations worldwide, forming strategic partnerships and collaborations to deliver high-quality pharmaceutical products to patients around the globe. Through a steadfast dedication to improving human health, Shionogi has become a respected name in the pharmaceutical field.

Shionogi & Co Ltd has achieved several significant milestones throughout its history. In recent years, the company successfully developed and gained approval for several groundbreaking medications, including the antiretroviral drug Delstrigo™ and the antibiotic Fetroja™. Shionogi has also established strategic partnerships with renowned pharmaceutical companies to enhance its research and development capabilities. Additionally, the company has been actively expanding its global reach, particularly in the United States and Europe, through various initiatives and collaborations. With an impressive track record of innovation and a commitment to improving global health, Shionogi & Co Ltd continues to make significant strides in the pharmaceutical industry.

Shionogi & Co Ltd is primarily present in Japan, where the company is headquartered.

Shionogi & Co Ltd represents values of innovation, integrity, and commitment to improving global health. The company's corporate philosophy is centered around the "Supplier of smiles" concept, aiming to contribute to the quality of life and healthcare of people worldwide. Shionogi is dedicated to delivering innovative pharmaceuticals and healthcare solutions, focusing on areas such as infectious diseases, cancer, pain management, and neuroscience. The company's emphasis on research and development, ethical practices, and strong partnerships enables Shionogi to fulfill its mission of creating a healthier future for society.

Analysts currently set an average price target of 3,178.69 JPY for the Shionogi & Co stock (median: 3,162.00 JPY), implying +8.6 % versus the latest price. The consensus is based on 17 analyst ratings.

Shionogi & Co Analyst Price Targets 2026

17 analysts currently rate the Shionogi & Co stock: 7 recommend buying, 10 holding and 0 selling. For 2026, analysts expect Shionogi & Co to generate revenue of 503.14 B JPY and earnings per share of 230.24 JPY.

Shionogi & Co Analyst Price Targets 2026

Converted at the current exchange rate, the Shionogi & Co share trades at 15.41 EUR (2,859.00 JPY).

The Shionogi & Co share (4507.T) is listed on 5 stock exchanges, including: Frankfurt (SH0.F), München (SH0.MU), Düsseldorf (SH0.DU).

Shionogi & Co Ltd is a Japanese pharmaceutical company based in Osaka. The company was founded in 1878 and specializes in the development and marketing of innovative drugs. Shionogi combines its own research capabilities with strategic partnerships with other companies. The business model of Shionogi is based on three core divisions: 1. Pharma: This division includes the clinical development and marketing of prescription drugs. Shionogi has a wide range of medications in various therapeutic areas such as oncology, infectious diseases, diabetes, cardiovascular diseases, and neurological diseases. One of Shionogi's most well-known medications is the antibiotic Fetroja for the treatment of respiratory and urinary tract infections. 2. Consumer Healthcare: This division includes the development and marketing of over-the-counter products such as dietary supplements or cosmetics. Some of Shionogi's well-known products include Dequadin lip balm, which helps with chapped lips and cold sores, and Allelock antiallergic medication used for allergic rhinitis. 3. Research & Development: This division focuses on the research and development of innovative drugs and therapy options. Shionogi invests a considerable portion of its revenue in research and development each year. The company also collaborates closely with academic institutions and other pharmaceutical companies to accelerate the research and development of new drugs. Additionally, Shionogi has a strong focus on the Asian market. The company has subsidiaries in several Asian countries and has made significant investments in research facilities in China and Singapore in recent years. In 2020, Shionogi had a revenue of approximately 1.1 trillion yen (around 8.6 billion euros) and employed around 6,000 people in Japan and worldwide. In summary, Shionogi's business model is based on the development and marketing of innovative drugs and therapy options. The company combines its own research capabilities with strategic partnerships and operates in three core divisions: Pharma, Consumer Healthcare, and Research & Development. Shionogi also has a strong presence in the Asian market and has invested in research facilities in China and Singapore in recent years.

The expected revenue of Shionogi & Co is 503.14 B JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Shionogi & Co is 195.92 B JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Shionogi & Co is currently 12.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Shionogi & Co stock.

The price-to-sales ratio (P/S) of Shionogi & Co is currently 4.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Shionogi & Co stock.

The Eulerpool Quality Score for Shionogi & Co is 7/10.

The ISIN of Shionogi & Co is JP3347200002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Shionogi & Co is 855648. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Shionogi & Co is 4507.T. The ticker symbol is used to trade Shionogi & Co shares on the stock exchange.

Over the past 12 months, Shionogi & Co paid a dividend of 66.00 JPY . This corresponds to a dividend yield of about 2.31 %. For the coming 12 months, Shionogi & Co is expected to pay a dividend of 124.80 JPY.

The current dividend yield of Shionogi & Co is 2.31 %.

Shionogi & Co pays a dividend, distributed in the months of , , , .

Shionogi & Co paid dividends every year for the past 36 years.

For the upcoming 12 months, dividends amounting to 124.80 JPY are expected. This corresponds to a dividend yield of 4.37 %.

Shionogi & Co is assigned to the 'Health' sector.

To receive the latest dividend of Shionogi & Co from amounting to 33 JPY, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Shionogi & Co distributed 50 JPY as dividends.

The dividends of Shionogi & Co are distributed in JPY.

All fundamentals and in-depth analysis of Shionogi & Co

Our stock analysis for Shionogi & Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shionogi & Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Shionogi & Co Stock
Shionogi & Co Revenue→
Shionogi & Co Stock
Shionogi & Co Net Income→
Shionogi & Co Stock
Shionogi & Co P/E→
Shionogi & Co Stock
Shionogi & Co P/S→
Shionogi & Co Stock
Shionogi & Co EBIT→
Shionogi & Co Stock
Shionogi & Co Dividend→
Shionogi & Co Stock
Shionogi & Co Directors Dealings→
Shionogi & Co Stock
Shionogi & Co Stocks→
Shionogi & Co Stock
Shionogi & Co Market capitalization→
Shionogi & Co Stock
Shionogi & Co Debt→
Shionogi & Co Stock
Shionogi & Co Liabilities→
Shionogi & Co Stock
Shionogi & Co Equity→
Shionogi & Co Stock
Shionogi & Co AAQS→
Shionogi & Co Stock
Shionogi & Co Employees→
Shionogi & Co Stock
Shionogi & Co ROE→
Shionogi & Co Stock
Shionogi & Co ROA→
Shionogi & Co Stock
Shionogi & Co ROCE→
Shionogi & Co Stock
Shionogi & Co News→
Shionogi & Co Stock
Shionogi & Co Analyst Price Targets→

Health Stocks

Ship Healthcare HoldingsShinva Medical Instrument CoShofuShinpoong Pharmaceutical CoShoulder InnovationsShinhung CoShouyao Holdings CoShine-On BioMedical CoShree Ganesh RemediesShin Nippon Biomedical LaboratoriesShree PacetronixShilpa MedicareAll Stocks A–Z →